用于治疗复发型多发性硬化症的β-干扰素制剂生物活性的体外评估。
In vitro assessment of the biologic activity of interferon beta formulations used for the treatment of relapsing multiple sclerosis.
作者信息
Scagnolari Carolina, Selvaggi Carla, Di Biase Emilia, Fraulo Maurizio, Dangond Fernando, Antonelli Guido
机构信息
a Department of Molecular Medicine , Sapienza University of Rome , Rome , Italy.
出版信息
J Immunoassay Immunochem. 2014;35(3):288-99. doi: 10.1080/15321819.2013.848815.
A new formulation (NF) of subcutaneous (sc) interferon (IFN) β-1a was developed in an attempt to improve injection tolerability and immunogenicity. We compared antiviral and IFNβ-stimulated gene (ISG) activities of IFNβ-1a sc NF with IFNβ-1a sc original formulation and IFNβ-1b sc. When equivalent unit amounts were compared, the IFNβ formulations demonstrated similar antiviral activity and induced similar levels of ISG mRNA. However, on a weight basis (ng/mL), significantly more IFNβ-1b sc was needed to equal the antiviral activity of either IFNβ-1a sc formulation, and both IFNβ-1a sc formulations induced significantly higher levels of ISG mRNA than IFNβ-1b sc.
为了提高注射耐受性和免疫原性，研发了一种皮下注射用干扰素β-1a的新剂型（NF）。我们比较了皮下注射干扰素β-1a新剂型、皮下注射干扰素β-1a原剂型和皮下注射干扰素β-1b的抗病毒活性以及干扰素β刺激基因（ISG）活性。当比较等效单位量时，各干扰素β制剂表现出相似的抗病毒活性，并诱导出相似水平的ISG mRNA。然而，以重量计（ng/mL），要达到与任一皮下注射干扰素β-1a制剂相同的抗病毒活性，皮下注射干扰素β-1b所需的量显著更多，且两种皮下注射干扰素β-1a制剂诱导的ISG mRNA水平均显著高于皮下注射干扰素β-1b。
Zotero 插件